Abrdn Life Sciences Investors
HQLFinancial ServicesNASDAQAsset Management · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the financial services sector, Abrdn Life Sciences Investors focuses on Asset Management services and products. Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The company carries a $522.4M market cap, placing it firmly in the small-cap category. The fund invests in public equity markets across the globe.
Market Cap
$522.4M
Beta
0.74
P/E (TTM)
6.16
P/E (Fwd)
—
EPS (TTM)
$2.79
EPS (Fwd)
—
ROE
17.6%
ROA
-0.4%
Cash
$75,538
Total Debt
$0
Free CF
-$2.2M
52W Change
36.9%
Annual Financials
Cash vs Debt
Abrdn Life Sciences Investors reports $76K in cash and $0 in total debt. Free cash flow is running at -$2.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 17.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$103.3M (2022) to $86.4M (2025), reflecting a 184% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Abrdn Life Sciences Investors and its sector.